Focused Ultrasound Foundation

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors

Retrieved on: 
Tuesday, January 23, 2024
Focused Ultrasound Foundation, Research, Corporation, Business administration, University, Regenerative medicine, Growth, Therapy, Disease, Cell, Senior, Health, Gene, Acquisition, ARM, Partnership, Management

CRANFORD, N.J., Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the nomination of seasoned pharmaceutical executive Robert J. Smith to its Board of Directors. The nomination of Mr. Smith is subject to shareholder approval at the Citius Annual Shareholders' Meeting to be held on March 12, 2024. Upon approval, the Citius Board of Directors will consist of seven members.

Key Points: 
  • CRANFORD, N.J., Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the nomination of seasoned pharmaceutical executive Robert J. Smith to its Board of Directors.
  • The nomination of Mr. Smith is subject to shareholder approval at the Citius Annual Shareholders' Meeting to be held on March 12, 2024.
  • Upon approval, the Citius Board of Directors will consist of seven members.
  • We are privileged to have an executive of Bob's caliber join our Board of Directors.

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights' Data

Retrieved on: 
Tuesday, May 30, 2023
Roswell Park Comprehensive Cancer Center, Focused Ultrasound Foundation, Partnership, Doctor of Pharmacy, University, CRC, Aster, American Society of Clinical Oncology, Cancer, Development of the human body, Research, Roswell Park, RNA, Immunotherapy, Doctor of Philosophy, AVATAR, ASCO, DO, Patient, Data, Sequence, Annual general meeting, Inherit, Genetic heterogeneity, Listeria monocytogenes non-coding RNA, H. Lee Moffitt Cancer Center & Research Institute, WES, Health, Society, Compugen (company), WTS, Pharmaceutical industry, Medical imaging, Vaccine

TAMPA, Fla., May 30, 2023 /PRNewswire/ -- Aster Insights ("the Company"), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago, IL. An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

Key Points: 
  • An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® ( ORIEN ) AVATAR program.
  • These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.
  • "We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights," said Jill Kolesar, PharmD, Director of the Precision Medicine Center at the Markey Cancer Center and Chair of the ORIEN Executive Advisory Committee.
  • For more information about our ASCO presentations, please contact Aster Insights at: [email protected]

INSIGHTEC CHAIRMAN OF THE BOARD AND CEO, MAURICE R. FERRÉ TO PRESENT AT 2023 MILKEN INSTITUTE GLOBAL CONFERENCE

Retrieved on: 
Friday, April 28, 2023
Focused Ultrasound Foundation, University, Therapy, University of Michigan, Stanford University, Disease, DSM-IV codes, Driving Towards the Daylight, Policy, Innovation system, ALS, PST, Biomedical engineering, Doctor of Philosophy, The Drive, Glioblastoma, Government, Associate, Essential tremor, BBB, Parkinson's disease, MD, Patient, Artificial intelligence, Growth, LOS, Alzheimer's disease, Health, The Beverly Hilton, Conference, Music, Chase Koch, Medical device, Radiology

LOS ANGELES, April 28, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using focused ultrasound technology to transform patient care, today announced that Maurice R. Ferré MD, the Chairman of the Board of Directors and CEO, will be a featured speaker at the 2023 Milken Institute Global Conference in Los Angeles, California on Monday, May 1, 2023 at 11:30 a.m. PST.  

Key Points: 
  • Dr. Maurice Ferré to join more than 900 leaders in business, government, philanthropy, health, and entertainment for four-day event focused on "Advancing a Thriving World"
    LOS ANGELES, April 28, 2023 /PRNewswire/ -- Insightec , a global healthcare company dedicated to using focused ultrasound technology to transform patient care, today announced that Maurice R. Ferré MD, the Chairman of the Board of Directors and CEO, will be a featured speaker at the 2023 Milken Institute Global Conference in Los Angeles, California on Monday, May 1, 2023 at 11:30 a.m. PST.
  • Dr. Ferré will join a panel discussion entitled, "The Drive Toward More Non-Invasive Treatments for Patients" to discuss recent advancements in focused ultrasound technology for the treatment of essential tremor , Parkinson's disease and other movement disorders.
  • Additionally, Dr. Ferré will highlight on-going clinical trials where focused ultrasound is combined with novel therapeutics for delivery across the blood brain barrier (BBB) in patients with glioblastoma, metastatic lung cancer, Alzheimer's Disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.
  • The conference will run April 30 - May 3 at The Beverly Hilton in Los Angeles, CA.

BioSig Announces New Advisory Board Member Lorraine Spurge

Retrieved on: 
Friday, March 24, 2023
McCaw Cellular Communications, Focused Ultrasound Foundation, Prostate Cancer Foundation, PURE, Advisory board, MGM Resorts International, MCI Communications, National Advisory Committee on Accounting Standards, Prostate cancer, WarnerMedia, Woman, Wall Street, American Dream, Money clip, MCI, CNN, CNBC, Drexel Burnham Lambert, Geffen Playhouse, Radio, Knowledge, Nautilus, Inc. v. Biosig Instruments, Inc., Growth, Book, Guggenheim Partners, Management, Movado

Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory Board.

Key Points: 
  • Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory Board.
  • After Drexel, she became an entrepreneur and helped build companies like International Capital Access, Spurge Ink!, MetWest Financial, and Guggenheim Partners.
  • “We are thrilled to welcome esteemed finance, investment, and business leader, Lorraine Spurge, to our Advisory Board,” said Ken Londoner, Chairman, CEO and Founder of BioSig.
  • I am pleased to join the Advisory Board with enthusiasm and a desire to help save lives.”

UK Focused Ultrasound Foundation Announces Launch

Retrieved on: 
Monday, January 30, 2023
Health Technology, Telemedicine, Virtual Medicine, Radiology, Pharmaceutical, Surgery, Oncology, Philanthropy, Medical Devices, Clinical Trials, Foundation, Biotechnology, Science, Other Science, Nursing, Research, Health, Prostate, National Health Service (England), Brain, House, NICE, Attention, Guys, MP, Institute of Cancer Research, Focused Ultrasound Foundation, National Institute for Health and Care Excellence, Myenteric plexus, Patient, Essential tremor, Hospital, Liver, Prostate cancer, Radiation, NHS, Civil service commission, Charity Commission for England and Wales, Pancreas, University of Oxford, HMRC, University, Neoplasm, Pancreatic cancer, Medical imaging

The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch.

Key Points: 
  • The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch.
  • “Our vision at the Foundation is for focused ultrasound to be used in the UK to improve the lives of millions of people afflicted with a wide variety of serious medical disorders in the shortest time possible,” said Foundation Chairman Philip Keevil.
  • It works closely with, but is independent of, the US-based Focused Ultrasound Foundation, aligning on goals and resources to advance focused ultrasound to treat millions worldwide.
  • UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London.